ICD-10 Title: Pulmonary coccidioidomycosis
ICD-10 B42.1 is a billable code used to indicate a diagnosis of icd-10 title: pulmonary coccidioidomycosis.
Pulmonary coccidioidomycosis, commonly known as valley fever, is a fungal infection caused by the inhalation of spores from the Coccidioides species, primarily C. immitis and C. posadasii. This condition predominantly affects the lungs and can lead to a range of respiratory symptoms, including cough, chest pain, fever, and fatigue. In immunocompromised patients, such as those with HIV/AIDS, cancer, or those on immunosuppressive therapy, the risk of severe disease increases significantly. The infection can progress to disseminated coccidioidomycosis, affecting other organs and leading to more severe complications. Diagnosis is typically confirmed through serological tests, culture, or histopathological examination. Treatment often involves antifungal medications such as fluconazole or itraconazole, especially in cases of moderate to severe disease or in immunocompromised individuals. Early recognition and appropriate management are crucial to prevent complications and improve patient outcomes.
Detailed clinical notes on the patient's history, symptoms, and diagnostic tests.
Patients presenting with respiratory symptoms in endemic areas, particularly in immunocompromised individuals.
Consideration of alternative diagnoses and the need for comprehensive follow-up.
Pulmonary function tests and imaging studies to assess lung involvement.
Patients with chronic cough and respiratory distress, especially in endemic regions.
Documentation of any pulmonary complications and response to treatment.
Used to confirm diagnosis in patients with respiratory symptoms.
Document the reason for testing and the patient's clinical presentation.
Infectious disease specialists should ensure comprehensive documentation of test results.
Common symptoms include cough, fever, chest pain, and fatigue. In some cases, patients may experience more severe respiratory distress.
Diagnosis is typically made through a combination of clinical evaluation, serological testing, and imaging studies such as chest X-rays or CT scans.
First-line treatments include fluconazole and itraconazole, especially in moderate to severe cases or in immunocompromised patients.
